TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
DBV Technologies SA – American ( (DBVT) ) has issued an update.
On September 18, 2025, DBV Technologies announced the resignation of Daniel Soland from its Board of Directors and compensation committee, effective immediately. Soland’s departure was amicable, and the company expressed gratitude for his contributions since 2015. The Board will continue with nine members and plans to appoint a new member to fill the vacancy, subject to shareholder approval at the next Annual General Meeting.
The most recent analyst rating on (DBVT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.
Spark’s Take on DBVT Stock
According to Spark, TipRanks’ AI Analyst, DBVT is a Neutral.
DBV Technologies SA’s overall stock score is primarily impacted by its financial instability and weak technical indicators. The positive corporate event provides some optimism, but the negative valuation and financial performance weigh heavily on the score.
To see Spark’s full report on DBVT stock, click here.
More about DBV Technologies SA – American
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is particularly known for its VIASKIN® patch technology, which aims to address food allergies through epicutaneous immunotherapy. DBV Technologies is headquartered in Châtillon, France, with operations in North America, and its shares are traded on Euronext Paris and the Nasdaq Capital Market.
Average Trading Volume: 32,981
Technical Sentiment Signal: Buy
Current Market Cap: $259.7M
For detailed information about DBVT stock, go to TipRanks’ Stock Analysis page.